Online Stockmarket Trading Update

BioDiem Ltd’s (BDM) lead product, the Live Attenuated Influenza Vaccine (LAIV) has been granted regulatory approval for marketing in India. “NasoVac” was launched this week by the Indian vaccine company, the Serum Institute of India. This is the first approval for marketing of BioDiem’s LAIV outside of Russia and the CIS. This comes as a result of SII’s licence for the development of an intranasal egg-based vaccine against the H1N1 influenza strain (swine flu) under WHO’s Pandemic Flu program. BioDiem is eligible to receive royalty payments on sales of this product in the private market.

BioDiem is an ASX-listed company, based in Melbourne, with an international focus on finding, adding value to and commercialising world-class research for vaccines, infectious diseases and other therapeutic areas. The company uses a cost-efficient approach to drug development through collaborations with academic centres of excellence, contract research organizations and partnerships with international pharmaceutical companies. BioDiem’s leading product is the Live Attenuated Influenza Vaccine (LAIV) technology, a novel intranasal vaccine being developed to prevent infection from endemic and pandemic influenza. The technology was licensed to BioDiem by the Institute of Experimental Medicine in St Petersburg. It has also been launched in India as NasoVac for protection against H1N1 influenza.

www.biodiem.com

http://www.traderdealer.com.au/Fundamentals/bdm

Tags: BDM, BioDiem, Government Approval, India, Influenza, Medical Supplies

This entry was posted on Tuesday, July 13th, 2010 at 7:08 am and is filed under ASX Company News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.